Loading...
Market
Will ArsenalBio launch a new T-cell medicine by the end of 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official press releases or announcements from ArsenalBio
Story
ArsenalBio Raises $325M in Series C, One of 2024's Largest Biotech Funding Rounds
Sep 4, 2024, 02:33 PM
ArsenalBio has successfully raised $325 million in a Series C financing round, marking one of the largest biotech funding rounds of the year. This investment will support the company's ongoing development efforts and scale its manufacturing capabilities for T-cell medicines. The funding round ranks as the fourth largest biotech raise of 2024, following Xaira Therapeutics' $1 billion, Mirador Therapeutics' $400 million, and Formation Bio's $372 million. ArsenalBio expressed gratitude to both new and existing investors for their support.
View original story
Similar markets
Yes • 50%
No • 50%
Q1 2026 • 25%
Q2 2026 • 25%
Q3 2026 • 25%
Q4 2026 or later • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Improved efficacy • 25%
Reduced side effects • 25%
Lower cost of treatment • 25%
Other • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%